IL273377B2 - Compositions comprising certirizine or levocertirizine for treating diarrhea - Google Patents
Compositions comprising certirizine or levocertirizine for treating diarrheaInfo
- Publication number
- IL273377B2 IL273377B2 IL273377A IL27337720A IL273377B2 IL 273377 B2 IL273377 B2 IL 273377B2 IL 273377 A IL273377 A IL 273377A IL 27337720 A IL27337720 A IL 27337720A IL 273377 B2 IL273377 B2 IL 273377B2
- Authority
- IL
- Israel
- Prior art keywords
- diarrhea
- pharmaceutical composition
- use according
- patient
- cetirizine
- Prior art date
Links
- 206010012735 Diarrhoea Diseases 0.000 title claims description 94
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 title claims description 40
- 229960001803 cetirizine Drugs 0.000 title claims description 39
- ZKLPARSLTMPFCP-OAQYLSRUSA-N 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1[C@@H](C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-OAQYLSRUSA-N 0.000 title claims description 4
- 229960001508 levocetirizine Drugs 0.000 title claims description 4
- 238000011282 treatment Methods 0.000 title description 49
- 238000002360 preparation method Methods 0.000 title description 2
- 229960001596 famotidine Drugs 0.000 claims description 30
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 claims description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims description 24
- 239000002552 dosage form Substances 0.000 claims description 18
- 208000019902 chronic diarrheal disease Diseases 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 229960000620 ranitidine Drugs 0.000 claims description 11
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 10
- 206010071282 Mastocytic enterocolitis Diseases 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
- 239000008103 glucose Substances 0.000 claims description 8
- 239000006186 oral dosage form Substances 0.000 claims description 8
- 201000009840 acute diarrhea Diseases 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 239000000310 rehydration solution Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 201000009863 inflammatory diarrhea Diseases 0.000 claims description 3
- 201000009881 secretory diarrhea Diseases 0.000 claims description 3
- 206010061958 Food Intolerance Diseases 0.000 claims description 2
- 201000000117 functional diarrhea Diseases 0.000 claims description 2
- 201000009868 osmotic diarrhea Diseases 0.000 claims description 2
- 208000028719 osmotic diarrheal disease Diseases 0.000 claims description 2
- 239000000938 histamine H1 antagonist Substances 0.000 description 21
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 18
- 230000007423 decrease Effects 0.000 description 16
- 108090000110 Histamine H1 Receptors Proteins 0.000 description 12
- 208000002551 irritable bowel syndrome Diseases 0.000 description 12
- 229940077716 histamine h2 receptor antagonists for peptic ulcer and gord Drugs 0.000 description 11
- 102000003834 Histamine H1 Receptors Human genes 0.000 description 10
- 239000000902 placebo Substances 0.000 description 10
- 229940068196 placebo Drugs 0.000 description 10
- 229940044551 receptor antagonist Drugs 0.000 description 10
- 239000002464 receptor antagonist Substances 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 231100000957 no side effect Toxicity 0.000 description 9
- 208000026775 severe diarrhea Diseases 0.000 description 9
- 239000005557 antagonist Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 208000011231 Crohn disease Diseases 0.000 description 7
- 206010020751 Hypersensitivity Diseases 0.000 description 7
- 230000001684 chronic effect Effects 0.000 description 7
- 229960000520 diphenhydramine Drugs 0.000 description 7
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 7
- 208000015943 Coeliac disease Diseases 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 206010009900 Colitis ulcerative Diseases 0.000 description 5
- 208000005156 Dehydration Diseases 0.000 description 5
- 244000134552 Plantago ovata Species 0.000 description 5
- 235000003421 Plantago ovata Nutrition 0.000 description 5
- 239000009223 Psyllium Substances 0.000 description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 description 5
- 230000007815 allergy Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- -1 opiates Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 229940070687 psyllium Drugs 0.000 description 5
- 102000000543 Histamine Receptors Human genes 0.000 description 4
- 108010002059 Histamine Receptors Proteins 0.000 description 4
- 206010067482 No adverse event Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000001078 anti-cholinergic effect Effects 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 229960001380 cimetidine Drugs 0.000 description 4
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 4
- 239000003792 electrolyte Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 210000003630 histaminocyte Anatomy 0.000 description 4
- 239000006215 rectal suppository Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 239000003793 antidiarrheal agent Substances 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 239000006189 buccal tablet Substances 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000007972 injectable composition Substances 0.000 description 3
- 208000029081 mast cell activation syndrome Diseases 0.000 description 3
- 210000001428 peripheral nervous system Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000006190 sub-lingual tablet Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 108010009685 Cholinergic Receptors Proteins 0.000 description 2
- 206010014418 Electrolyte imbalance Diseases 0.000 description 2
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 102000034337 acetylcholine receptors Human genes 0.000 description 2
- 230000001142 anti-diarrhea Effects 0.000 description 2
- 229940125714 antidiarrheal agent Drugs 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 229940090012 bentyl Drugs 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000002052 colonoscopy Methods 0.000 description 2
- CURUTKGFNZGFSE-UHFFFAOYSA-N dicyclomine Chemical group C1CCCCC1C1(C(=O)OCCN(CC)CC)CCCCC1 CURUTKGFNZGFSE-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000000350 mc(t) Anatomy 0.000 description 2
- 208000008275 microscopic colitis Diseases 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 229940097496 nasal spray Drugs 0.000 description 2
- 229940127240 opiate Drugs 0.000 description 2
- 229940100688 oral solution Drugs 0.000 description 2
- 229940100692 oral suspension Drugs 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 description 1
- 108010019625 Atazanavir Sulfate Proteins 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 206010056979 Colitis microscopic Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000014997 Crohn colitis Diseases 0.000 description 1
- 208000006343 Cutaneous Mastocytosis Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000224466 Giardia Species 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 description 1
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 description 1
- 238000001295 Levene's test Methods 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- PVLJETXTTWAYEW-UHFFFAOYSA-N Mizolastine Chemical compound N=1C=CC(=O)NC=1N(C)C(CC1)CCN1C1=NC2=CC=CC=C2N1CC1=CC=C(F)C=C1 PVLJETXTTWAYEW-UHFFFAOYSA-N 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- IJHNSHDBIRRJRN-UHFFFAOYSA-N N,N-dimethyl-3-phenyl-3-(2-pyridinyl)-1-propanamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=CC=C1 IJHNSHDBIRRJRN-UHFFFAOYSA-N 0.000 description 1
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 1
- ISFHAYSTHMVOJR-UHFFFAOYSA-N Phenindamine Chemical compound C1N(C)CCC(C2=CC=CC=C22)=C1C2C1=CC=CC=C1 ISFHAYSTHMVOJR-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010041969 Steatorrhoea Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 201000008736 Systemic mastocytosis Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960003792 acrivastine Drugs 0.000 description 1
- PWACSDKDOHSSQD-IUTFFREVSA-N acrivastine Chemical compound C1=CC(C)=CC=C1C(\C=1N=C(\C=C\C(O)=O)C=CC=1)=C/CN1CCCC1 PWACSDKDOHSSQD-IUTFFREVSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 description 1
- 229960003277 atazanavir Drugs 0.000 description 1
- 229960000383 azatadine Drugs 0.000 description 1
- SEBMTIQKRHYNIT-UHFFFAOYSA-N azatadine Chemical compound C1CN(C)CCC1=C1C2=NC=CC=C2CCC2=CC=CC=C21 SEBMTIQKRHYNIT-UHFFFAOYSA-N 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002071 bepotastine Drugs 0.000 description 1
- YWGDOWXRIALTES-NRFANRHFSA-N bepotastine Chemical compound C1CN(CCCC(=O)O)CCC1O[C@H](C=1N=CC=CC=1)C1=CC=C(Cl)C=C1 YWGDOWXRIALTES-NRFANRHFSA-N 0.000 description 1
- 229960004314 bilastine Drugs 0.000 description 1
- ACCMWZWAEFYUGZ-UHFFFAOYSA-N bilastine Chemical compound N=1C2=CC=CC=C2N(CCOCC)C=1C(CC1)CCN1CCC1=CC=C(C(C)(C)C(O)=O)C=C1 ACCMWZWAEFYUGZ-UHFFFAOYSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229960000725 brompheniramine Drugs 0.000 description 1
- ZDIGNSYAACHWNL-UHFFFAOYSA-N brompheniramine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 ZDIGNSYAACHWNL-UHFFFAOYSA-N 0.000 description 1
- 229960000428 carbinoxamine Drugs 0.000 description 1
- OJFSXZCBGQGRNV-UHFFFAOYSA-N carbinoxamine Chemical compound C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 OJFSXZCBGQGRNV-UHFFFAOYSA-N 0.000 description 1
- 229960004342 cetirizine hydrochloride Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 229960002881 clemastine Drugs 0.000 description 1
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000008609 collagenous colitis Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 229960001140 cyproheptadine Drugs 0.000 description 1
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 229960001271 desloratadine Drugs 0.000 description 1
- 229960002691 dexbrompheniramine Drugs 0.000 description 1
- ZDIGNSYAACHWNL-HNNXBMFYSA-N dexbrompheniramine Chemical compound C1([C@H](CCN(C)C)C=2N=CC=CC=2)=CC=C(Br)C=C1 ZDIGNSYAACHWNL-HNNXBMFYSA-N 0.000 description 1
- 229960001882 dexchlorpheniramine Drugs 0.000 description 1
- SOYKEARSMXGVTM-HNNXBMFYSA-N dexchlorpheniramine Chemical compound C1([C@H](CCN(C)C)C=2N=CC=CC=2)=CC=C(Cl)C=C1 SOYKEARSMXGVTM-HNNXBMFYSA-N 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 235000001434 dietary modification Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 229960001971 ebastine Drugs 0.000 description 1
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 description 1
- 238000009112 empiric therapy Methods 0.000 description 1
- 208000037902 enteropathy Diseases 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 229960003592 fexofenadine Drugs 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 201000006592 giardiasis Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960000930 hydroxyzine Drugs 0.000 description 1
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 208000004341 lymphocytic colitis Diseases 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960000582 mepyramine Drugs 0.000 description 1
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 1
- 229940042003 metamucil Drugs 0.000 description 1
- 229960001144 mizolastine Drugs 0.000 description 1
- 229960004872 nizatidine Drugs 0.000 description 1
- SGXXNSQHWDMGGP-IZZDOVSWSA-N nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229960003534 phenindamine Drugs 0.000 description 1
- 229960001190 pheniramine Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- 229960004466 quifenadine Drugs 0.000 description 1
- PZMAHNDJABQWGS-UHFFFAOYSA-N quifenadine Chemical compound C1N(CC2)CCC2C1C(O)(C=1C=CC=CC=1)C1=CC=CC=C1 PZMAHNDJABQWGS-UHFFFAOYSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229960001520 ranitidine hydrochloride Drugs 0.000 description 1
- GGWBHVILAJZWKJ-KJEVSKRMSA-N ranitidine hydrochloride Chemical compound [H+].[Cl-].[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 GGWBHVILAJZWKJ-KJEVSKRMSA-N 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 229960005328 rupatadine Drugs 0.000 description 1
- WUZYKBABMWJHDL-UHFFFAOYSA-N rupatadine Chemical compound CC1=CN=CC(CN2CCC(CC2)=C2C3=NC=CC=C3CCC3=CC(Cl)=CC=C32)=C1 WUZYKBABMWJHDL-UHFFFAOYSA-N 0.000 description 1
- 230000000580 secretagogue effect Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 208000001162 steatorrhea Diseases 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000021092 sugar substitutes Nutrition 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 229960000351 terfenadine Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960001128 triprolidine Drugs 0.000 description 1
- CBEQULMOCCWAQT-WOJGMQOQSA-N triprolidine Chemical compound C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C/CN1CCCC1 CBEQULMOCCWAQT-WOJGMQOQSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361782608P | 2013-03-14 | 2013-03-14 | |
| PCT/US2014/027323 WO2014152420A2 (en) | 2013-03-14 | 2014-03-14 | Product and method for treating diarrhea |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL273377A IL273377A (en) | 2020-05-31 |
| IL273377B1 IL273377B1 (en) | 2023-06-01 |
| IL273377B2 true IL273377B2 (en) | 2023-10-01 |
Family
ID=50680150
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL273377A IL273377B2 (en) | 2013-03-14 | 2014-03-14 | Compositions comprising certirizine or levocertirizine for treating diarrhea |
| IL241372A IL241372B (en) | 2013-03-14 | 2015-09-09 | An h1 receptor antagonist and an h2 receptor antagonist for use in the treatment of diarrhea |
| IL256300A IL256300B (en) | 2013-03-14 | 2017-12-13 | Antagonist of the 1h receptor and antagonist of the 2h receptor for use in the treatment of a patient suffering from chronic idiopathic diarrhea |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL241372A IL241372B (en) | 2013-03-14 | 2015-09-09 | An h1 receptor antagonist and an h2 receptor antagonist for use in the treatment of diarrhea |
| IL256300A IL256300B (en) | 2013-03-14 | 2017-12-13 | Antagonist of the 1h receptor and antagonist of the 2h receptor for use in the treatment of a patient suffering from chronic idiopathic diarrhea |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US9717726B2 (enExample) |
| EP (3) | EP3269364B1 (enExample) |
| JP (4) | JP6313417B2 (enExample) |
| KR (4) | KR20180088514A (enExample) |
| CN (2) | CN108939076A (enExample) |
| AU (3) | AU2014239878B2 (enExample) |
| BR (2) | BR122017004716A2 (enExample) |
| CA (1) | CA2906005C (enExample) |
| DK (1) | DK2968205T3 (enExample) |
| ES (2) | ES2655505T3 (enExample) |
| HK (1) | HK1247557B (enExample) |
| HU (1) | HUE035201T2 (enExample) |
| IL (3) | IL273377B2 (enExample) |
| MX (2) | MX366329B (enExample) |
| MY (1) | MY175326A (enExample) |
| PL (1) | PL2968205T3 (enExample) |
| PT (1) | PT2968205T (enExample) |
| RU (1) | RU2015143475A (enExample) |
| WO (1) | WO2014152420A2 (enExample) |
| ZA (1) | ZA201708539B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9717726B2 (en) | 2013-03-14 | 2017-08-01 | Maregade Rx, LLC | Product and method for treating diarrhea |
| US20150132410A1 (en) * | 2013-11-14 | 2015-05-14 | Michael M. Jacobs | Compositions and methods for the prevention and treatment of alcohol-induced hangover syndrome |
| US20180185356A1 (en) * | 2016-12-23 | 2018-07-05 | Maregade Rx, LLC | Low dose product and method for treating diarrhea |
| IT201900012645A1 (it) * | 2019-07-23 | 2021-01-23 | Eros Zanotti | Una composizione farmaceutica per l'uso nel trattamento delle chinetosi |
| CN112616320B (zh) * | 2019-08-05 | 2024-04-05 | 株式会社日立高新技术 | 等离子处理装置 |
| CN115515435A (zh) * | 2020-02-11 | 2022-12-23 | 沃尔夫森医疗中心 | 有效治疗溃疡性结肠炎的方法 |
| CN117280446A (zh) | 2021-08-23 | 2023-12-22 | 株式会社日立高新技术 | 等离子处理装置以及等离子处理方法 |
| WO2023049205A1 (en) | 2021-09-22 | 2023-03-30 | Hista Rx Llc | Compositions and methods for treating and preventing interstitial cystitis |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1832287A2 (en) * | 2001-11-23 | 2007-09-12 | Janssen Pharmaceutica N.V. | The use of anti-histaminics for acute reduction of elevated intracranial pressure |
| US20090312358A1 (en) * | 2006-03-22 | 2009-12-17 | Trustees Of Boston University | Method for management of diarrhea |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5204118A (en) | 1989-11-02 | 1993-04-20 | Mcneil-Ppc, Inc. | Pharmaceutical compositions and methods for treating the symptoms of overindulgence |
| US5096894A (en) * | 1990-04-03 | 1992-03-17 | Bristol-Myers Squibb Company | Rice dextrin oral rehydration solution |
| AU7255094A (en) | 1993-07-06 | 1995-02-06 | Mcneil-Ppc, Inc. | H2 antagonist-antihistamine combinations |
| US6264984B1 (en) * | 1999-12-06 | 2001-07-24 | Bristol-Myers Squibb Company | Effervescent histamine H2 antagonist composition |
| US6656492B2 (en) * | 2000-06-30 | 2003-12-02 | Yamanouchi Pharmaceutical Co., Ltd. | Quick disintegrating tablet in buccal cavity and manufacturing method thereof |
| CA2430292A1 (en) | 2000-11-30 | 2002-06-06 | The Bio Balance Corp. | Preparation of compositions comprising bacterial strains and volatile plant extracts and therapeutic and industrial applications thereof |
| SE528789C2 (sv) | 2004-09-10 | 2007-02-13 | Sandvik Intellectual Property | PVD-belagt skär av hårdmetall samt sätt att tillverka detta |
| US20070077300A1 (en) * | 2005-09-30 | 2007-04-05 | Wynn David W | Oral compositions containing a salivation inducing agent |
| US8207188B2 (en) | 2006-04-07 | 2012-06-26 | Michalis Nicolaou | Treatment of diseases modulated by a H4 receptor agonist |
| US8207292B2 (en) | 2007-02-12 | 2012-06-26 | Michalis Nicolaou | Treatment of COPD, gastro-esophageal reflux disease (GERD), food allergies and other gastrointestinal conditions and disorders ameliorated by proper histamine management using a combination of histidine decarboxylase inhibitors, LRA drugs, anti-H1 and/or anti-H2 drugs |
| US20070254050A1 (en) * | 2006-05-01 | 2007-11-01 | Quart Barry D | Method for treatment of diarrhea-predominant irritable bowel syndrome |
| US20090042972A1 (en) * | 2006-05-19 | 2009-02-12 | Somaxon Pharmaceuticals, Inc. | Methods of using low-dose doxepin for the improvement of sleep |
| CA2721133C (en) * | 2007-04-13 | 2018-11-06 | Somaxon Pharmaceuticals, Inc. | Low-dose doxepin formulations and methods of making and using the same |
| US8263581B2 (en) | 2009-07-03 | 2012-09-11 | Jdp Therapeutics, Inc. | Non-sedating antihistamine injection formulations and methods of use thereof |
| EP3415627A1 (en) | 2012-11-13 | 2018-12-19 | Codiak BioSciences, Inc. | Delivery of therapeutic agent |
| US9717726B2 (en) | 2013-03-14 | 2017-08-01 | Maregade Rx, LLC | Product and method for treating diarrhea |
| US20180185356A1 (en) | 2016-12-23 | 2018-07-05 | Maregade Rx, LLC | Low dose product and method for treating diarrhea |
-
2014
- 2014-03-13 US US14/209,937 patent/US9717726B2/en active Active
- 2014-03-14 KR KR1020187021688A patent/KR20180088514A/ko not_active Ceased
- 2014-03-14 EP EP17189072.6A patent/EP3269364B1/en active Active
- 2014-03-14 HU HUE14722445A patent/HUE035201T2/hu unknown
- 2014-03-14 KR KR1020207023569A patent/KR20200100211A/ko not_active Ceased
- 2014-03-14 JP JP2016502404A patent/JP6313417B2/ja active Active
- 2014-03-14 MY MYPI2015703092A patent/MY175326A/en unknown
- 2014-03-14 RU RU2015143475A patent/RU2015143475A/ru not_active Application Discontinuation
- 2014-03-14 CN CN201810755897.7A patent/CN108939076A/zh active Pending
- 2014-03-14 BR BR122017004716-7A patent/BR122017004716A2/pt not_active Application Discontinuation
- 2014-03-14 CA CA2906005A patent/CA2906005C/en active Active
- 2014-03-14 IL IL273377A patent/IL273377B2/en unknown
- 2014-03-14 WO PCT/US2014/027323 patent/WO2014152420A2/en not_active Ceased
- 2014-03-14 KR KR1020217004881A patent/KR102449977B1/ko active Active
- 2014-03-14 EP EP14722445.5A patent/EP2968205B1/en active Active
- 2014-03-14 MX MX2017011532A patent/MX366329B/es unknown
- 2014-03-14 BR BR112015022513A patent/BR112015022513A2/pt not_active Application Discontinuation
- 2014-03-14 KR KR1020157029028A patent/KR101884506B1/ko active Active
- 2014-03-14 AU AU2014239878A patent/AU2014239878B2/en active Active
- 2014-03-14 DK DK14722445.5T patent/DK2968205T3/da active
- 2014-03-14 CN CN201480022471.0A patent/CN105324112B/zh active Active
- 2014-03-14 PT PT147224455T patent/PT2968205T/pt unknown
- 2014-03-14 EP EP19169633.5A patent/EP3581205A3/en active Pending
- 2014-03-14 PL PL14722445T patent/PL2968205T3/pl unknown
- 2014-03-14 MX MX2015011885A patent/MX350814B/es active IP Right Grant
- 2014-03-14 ES ES14722445.5T patent/ES2655505T3/es active Active
- 2014-03-14 ES ES17189072T patent/ES2743604T3/es active Active
-
2015
- 2015-09-09 IL IL241372A patent/IL241372B/en active IP Right Grant
-
2016
- 2016-09-06 US US15/257,674 patent/US10034875B2/en active Active
-
2017
- 2017-10-24 AU AU2017251701A patent/AU2017251701B2/en active Active
- 2017-12-13 IL IL256300A patent/IL256300B/en active IP Right Grant
- 2017-12-15 ZA ZA2017/08539A patent/ZA201708539B/en unknown
-
2018
- 2018-03-22 JP JP2018054088A patent/JP6473254B2/ja active Active
- 2018-05-28 HK HK18106976.5A patent/HK1247557B/en unknown
- 2018-07-06 US US16/029,384 patent/US11058681B2/en active Active
-
2019
- 2019-01-24 JP JP2019009896A patent/JP6790140B2/ja active Active
- 2019-02-28 AU AU2019201412A patent/AU2019201412A1/en not_active Abandoned
-
2020
- 2020-11-04 JP JP2020184294A patent/JP2021046400A/ja active Pending
-
2021
- 2021-05-28 US US17/333,525 patent/US20220047583A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1832287A2 (en) * | 2001-11-23 | 2007-09-12 | Janssen Pharmaceutica N.V. | The use of anti-histaminics for acute reduction of elevated intracranial pressure |
| US20090312358A1 (en) * | 2006-03-22 | 2009-12-17 | Trustees Of Boston University | Method for management of diarrhea |
Non-Patent Citations (1)
| Title |
|---|
| SHRIRAM JAKATE ET AL,, MASTOCYTIC ENTEROCOLITIS: INCREASED MUCOSAL MAST CELLS IN CHRONIC INTRACTABLE DIARRHEA, 1 March 2006 (2006-03-01) * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273377B1 (en) | A preparation containing cetirizine or levocetirizine for the treatment of diarrhea | |
| IL257276A (en) | Methods for treating Knox-Gestaut syndrome using penforamine | |
| HK1247557A1 (en) | Product and method for treating diarrhea | |
| IL311682A (en) | Methods for treating chronic kidney disease with dapagliflozin | |
| EP3558296B1 (en) | Low dose product and method for treating diarrhea | |
| HK1213205B (en) | Product and method for treating diarrhea | |
| IL324509A (en) | Methods for treating multiple sclerosis relapse using a Bruton's tyrosine kinase inhibitor |